James S Minnion

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4783121/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Gut hormone PYY3-36 physiologically inhibits food intake. Nature, 2002, 418, 650-654.	27.8	2,039
2	Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults. Gut, 2015, 64, 1744-1754.	12.1	950
3	The inhibitory effects of peripheral administration of peptide YY3–36 and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal–brainstem–hypothalamic pathway. Brain Research, 2005, 1044, 127-131.	2.2	494
4	Oxyntomodulin Suppresses Appetite and Reduces Food Intake in Humans. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 4696-4701.	3.6	406
5	Subcutaneous Oxyntomodulin Reduces Body Weight in Overweight and Obese Subjects. Diabetes, 2005, 54, 2390-2395.	0.6	383
6	Peripheral Oxyntomodulin Reduces Food Intake and Body Weight Gain in Rats. Endocrinology, 2004, 145, 2687-2695.	2.8	285
7	Postembryonic ablation of AgRP neurons in mice leads to a lean, hypophagic phenotype. FASEB Journal, 2005, 19, 1680-1682.	0.5	215
8	Hypothalamic neuropeptides and the regulation of appetite. Neuropharmacology, 2012, 63, 18-30.	4.1	199
9	Coadministration of Glucagon-Like Peptide-1 During Glucagon Infusion in Humans Results in Increased Energy Expenditure and Amelioration of Hyperglycemia. Diabetes, 2013, 62, 1131-1138.	0.6	182
10	Fermentable carbohydrate stimulates FFAR2-dependent colonic PYY cell expansionÂtoÂincrease satiety. Molecular Metabolism, 2017, 6, 48-60.	6.5	179
11	Targeting GLP-1 receptor trafficking to improve agonist efficacy. Nature Communications, 2018, 9, 1602.	12.8	162
12	Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet, The, 2017, 389, 1809-1820.	13.7	149
13	Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of Ovarian Hyperstimulation Syndrome (OHSS) During In Vitro Fertilization (IVF) Therapy. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3322-3331.	3.6	135
14	Coinfusion of Low-Dose GLP-1 and Glucagon in Man Results in a Reduction in Food Intake. Diabetes, 2014, 63, 3711-3720.	0.6	119
15	Repeated ICV administration of oxyntomodulin causes a greater reduction in body weight gain than in pair-fed rats. American Journal of Physiology - Endocrinology and Metabolism, 2002, 283, E1173-E1177.	3.5	116
16	Ghrelin mimics fasting to enhance human hedonic, orbitofrontal cortex, and hippocampal responses to food. American Journal of Clinical Nutrition, 2014, 99, 1319-1330.	4.7	116
17	Neurokinin B Administration Induces Hot Flushes in Women. Scientific Reports, 2015, 5, 8466.	3.3	96
18	Bile acids and the metabolic syndrome. Annals of Clinical Biochemistry, 2019, 56, 326-337.	1.6	91

#	Article	IF	CITATIONS
19	Peripheral and Central Administration of Xenin and Neurotensin Suppress Food Intake in Rodents. Obesity, 2009, 17, 1135-1143.	3.0	89
20	Combined GLP-1, Oxyntomodulin, and Peptide YY Improves Body Weight and Glycemia in Obesity and Prediabetes/Type 2 Diabetes: A Randomized, Single-Blinded, Placebo-Controlled Study. Diabetes Care, 2019, 42, 1446-1453.	8.6	84
21	Optical Control of Insulin Secretion Using an Incretin Switch. Angewandte Chemie - International Edition, 2015, 54, 15565-15569.	13.8	80
22	Investigation of Structure-Activity Relationships of Oxyntomodulin (Oxm) Using Oxm Analogs. Endocrinology, 2009, 150, 1712-1721.	2.8	77
23	Differential hypothalamic neuronal activation following peripheral injection of GLP-1 and oxyntomodulin in mice detected by manganese-enhanced magnetic resonance imaging. Biochemical and Biophysical Research Communications, 2006, 350, 298-306.	2.1	73
24	The Effect of a Subcutaneous Infusion of GLP-1, OXM, and PYY on Energy Intake and Expenditure in Obese Volunteers. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2364-2372.	3.6	72
25	Control of insulin secretion by GLP-1. Peptides, 2018, 100, 75-84.	2.4	69
26	Kisspeptin signaling in the amygdala modulates reproductive hormone secretion. Brain Structure and Function, 2016, 221, 2035-2047.	2.3	66
27	A second dose of kisspeptin-54 improves oocyte maturation in women at high risk of ovarian hyperstimulation syndrome: a Phase 2 randomized controlled trial. Human Reproduction, 2017, 32, 1915-1924.	0.9	64
28	Agonist-induced membrane nanodomain clustering drives GLP-1 receptor responses in pancreatic beta cells. PLoS Biology, 2019, 17, e3000097.	5.6	61
29	Roles of increased glycaemic variability, GLP-1 and glucagon in hypoglycaemia after Roux-en-Y gastric bypass. European Journal of Endocrinology, 2017, 177, 455-464.	3.7	50
30	The Obesity Epidemic: Pharmacological Challenges. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2008, 8, 82-98.	3.4	49
31	The New Era of Drug Therapy for Obesity: The Evidence and the Expectations. Drugs, 2015, 75, 935-945.	10.9	46
32	Allosteric Optical Control of a Class B Gâ€Protein oupled Receptor. Angewandte Chemie - International Edition, 2016, 55, 5865-5868.	13.8	45
33	Overexpression of CART in the PVN Increases Food Intake and Weight Gain in Rats. Obesity, 2008, 16, 2239-2244.	3.0	44
34	A Targeted RNAi Screen Identifies Endocytic Trafficking Factors That Control GLP-1 Receptor Signaling in Pancreatic β-Cells. Diabetes, 2018, 67, 385-399.	0.6	41
35	Genetic and biased agonist-mediated reductions in β-arrestin recruitment prolong cAMP signaling at glucagon family receptors. Journal of Biological Chemistry, 2021, 296, 100133.	3.4	41
36	The neuroendocrine physiology of kisspeptin in the human. Reviews in Endocrine and Metabolic Disorders, 2007, 8, 41-46.	5.7	38

#	Article	IF	CITATIONS
37	Investigating the KNDy Hypothesis in Humans by Coadministration of Kisspeptin, Neurokinin B, and Naltrexone in Men. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3429-3436.	3.6	37
38	<p>CBD Effects on TRPV1 Signaling Pathways in Cultured DRG Neurons</p> . Journal of Pain Research, 2020, Volume 13, 2269-2278.	2.0	36
39	Signalling, trafficking and glucoregulatory properties of glucagonâ€ike peptideâ€1 receptor agonists exendinâ€4 and lixisenatide. British Journal of Pharmacology, 2020, 177, 3905-3923.	5.4	36
40	Differentiating constitutional thinness from anorexia nervosa in DSM 5 era. Psychoneuroendocrinology, 2017, 84, 94-100.	2.7	35
41	Insights into the role of neuronal glucokinase. American Journal of Physiology - Endocrinology and Metabolism, 2016, 311, E42-E55.	3.5	33
42	RAMP2 Influences Glucagon Receptor Pharmacology via Trafficking and Signaling. Endocrinology, 2017, 158, 2680-2693.	2.8	33
43	Kisspeptin Expression in the Human Infundibular Nucleus in Relation to Sex, Gender Identity, and Sexual Orientation. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2380-2389.	3.6	32
44	Disconnect between signalling potency and inÂvivo efficacy of pharmacokinetically optimised biased glucagon-like peptide-1 receptor agonists. Molecular Metabolism, 2020, 37, 100991.	6.5	32
45	The Influence of Peptide Context on Signaling and Trafficking of Glucagon-like Peptide-1 Receptor Biased Agonists. ACS Pharmacology and Translational Science, 2020, 3, 345-360.	4.9	32
46	Subcutaneous infusion of kisspeptinâ€54 stimulates gonadotrophin release in women and the response correlates with basal oestradiol levels. Clinical Endocrinology, 2016, 84, 939-945.	2.4	31
47	Potent Prearranged Positive Allosteric Modulators of the Glucagonâ€like Peptideâ€1 Receptor. ChemistryOpen, 2017, 6, 501-505.	1.9	31
48	The effects of kisspeptinâ€54 on blood pressure in humans and plasma kisspeptin concentrations in hypertensive diseases of pregnancy. British Journal of Clinical Pharmacology, 2010, 70, 674-681.	2.4	30
49	Pharmacokinetics, adverse effects and tolerability of a novel analogue of human pancreatic polypeptide, PP 1420. British Journal of Clinical Pharmacology, 2012, 73, 232-239.	2.4	30
50	Postprandial ghrelin, cholecystokinin, peptide YY, and appetite before and after weight loss in overweight women with and without polycystic ovary syndrome. American Journal of Clinical Nutrition, 2007, 86, 1603-1610.	4.7	30
51	The effect of slow spaced eating on hunger and satiety in overweight and obese patients with type 2 diabetes mellitus. BMJ Open Diabetes Research and Care, 2014, 2, e000013.	2.8	28
52	Ligand-Specific Factors Influencing GLP-1 Receptor Post-Endocytic Trafficking and Degradation in Pancreatic Beta Cells. International Journal of Molecular Sciences, 2020, 21, 8404.	4.1	28
53	Combination of Peptide YY _{3–36} with GLP-1 _{7–36 amide} Causes an Increase in First-Phase Insulin Secretion after IV Glucose. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E2317-E2324.	3.6	27
54	Modulations of human resting brain connectivity by kisspeptin enhance sexual and emotional functions. JCI Insight, 2018, 3, .	5.0	26

#	Article	IF	CITATIONS
55	Thyroid Hormone Receptor Beta in the Ventromedial Hypothalamus Is Essential for the Physiological Regulation of Food Intake and Body Weight. Cell Reports, 2017, 19, 2202-2209.	6.4	25
56	Oxyntomodulin. Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders, 2006, 5, 265-272.	1.8	23
57	Receptor Activity-Modifying Protein 2 (RAMP2) alters glucagon receptor trafficking in hepatocytes with functional effects on receptor signalling. Molecular Metabolism, 2021, 53, 101296.	6.5	23
58	No Guts, No Loss: Toward the Ideal Treatment for Obesity in the Twenty-First Century. Frontiers in Endocrinology, 2018, 9, 442.	3.5	22
59	Colocalization of Cocaine- and Amphetamine-Regulated Transcript with Kisspeptin and Neurokinin B in the Human Infundibular Region. PLoS ONE, 2014, 9, e103977.	2.5	21
60	Ghrelin and peptide YY (PYY) profiles in gastrointestinal tissues and the circulation of the rat during pregnancy and lactation. Peptides, 2009, 30, 2213-2220.	2.4	20
61	Intracerebroventricular administration of vasoactive intestinal peptide inhibits food intake. Regulatory Peptides, 2011, 172, 8-15.	1.9	20
62	Appetite and Hedonism: Gut Hormones and the Brain. Endocrinology and Metabolism Clinics of North America, 2010, 39, 729-743.	3.2	18
63	Lâ€Arginine Increases Postprandial Circulating GLPâ€1 and PYY Levels in Humans. Obesity, 2018, 26, 1721-1726.	3.0	18
64	Degradation Paradigm of the Gut Hormone, Pancreatic Polypeptide, by Hepatic and Renal Peptidases. Endocrinology, 2017, 158, 1755-1765.	2.8	16
65	The Metabolomic Effects of Tripeptide Gut Hormone Infusion Compared to Roux-en-Y Gastric Bypass and Caloric Restriction. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e767-e782.	3.6	16
66	Resistance to lean mass gain in constitutional thinness in freeâ€ŀiving conditions is not overpassed by overfeeding. Journal of Cachexia, Sarcopenia and Muscle, 2020, 11, 1187-1199.	7.3	14
67	Abnormalities of the hypothalamo-pituitary-thyroid axis in the pro-opiomelanocortin deficient mouse. Regulatory Peptides, 2004, 122, 169-172.	1.9	13
68	Acylation of the Incretin Peptide Exendin-4 Directly Impacts Glucagon-Like Peptide-1 Receptor Signaling and Trafficking. Molecular Pharmacology, 2021, 100, 319-334.	2.3	13
69	Proglucagon Promoter Cre-Mediated AMPK Deletion in Mice Increases Circulating GLP-1 Levels and Oral Glucose Tolerance. PLoS ONE, 2016, 11, e0149549.	2.5	13
70	The identification of elevated urinary kisspeptin-immunoreactivity during pregnancy. Annals of Clinical Biochemistry, 2015, 52, 395-398.	1.6	11
71	Effects of Glucagon-like Peptide-1 on the Reproductive Axis in Healthy Men. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 1119-1125.	3.6	11
72	Quantification of Rat Kisspeptin Using a Novel Radioimmunoassay. PLoS ONE, 2014, 9, e97611.	2.5	11

#	Article	IF	CITATIONS
73	Approaches to the pharmacological treatment of obesity. Expert Review of Clinical Pharmacology, 2010, 3, 73-88.	3.1	10
74	The Peutz-Jeghers kinase LKB1 suppresses polyp growth from intestinal cells of a proglucagon-expressing lineage. DMM Disease Models and Mechanisms, 2014, 7, 1275-86.	2.4	10
75	Allosterische optische Steuerung eines Klasseâ€Bâ€Gâ€Proteinâ€gekoppelten Rezeptors. Angewandte Chemie, 2016, 128, 5961-5965.	2.0	10
76	The preanalytical stability of glucagon as measured by liquid chromatography tandem mass spectrometry and two commercially available immunoassays. Annals of Clinical Biochemistry, 2017, 54, 293-296.	1.6	9
77	Evaluation of efficacy- versus affinity-driven agonism with biased GLP-1R ligands P5 and exendin-F1. Biochemical Pharmacology, 2021, 190, 114656.	4.4	8
78	Investigating the Glucagon Receptor and Glucagon-Like Peptide 1 Receptor Activity of Oxyntomodulin-Like Analogues in Male Wistar Rats. Current Therapeutic Research, 2015, 77, 111-115.	1.2	7
79	Influence of Cholecystokinin-8 on Compound Nerve Action Potentials from Ventral Gastric Vagus in Rats. International Journal of Neural Systems, 2018, 28, 1850006.	5.2	7
80	What Can We Learn From Mouse Models About Bile Acid–Mediated Changes After Bariatric Surgery?. Gastroenterology, 2019, 157, 4-8.	1.3	7
81	Partial agonism improves the anti-hyperglycaemic efficacy of an oxyntomodulin-derived GLP-1R/GCGR co-agonist. Molecular Metabolism, 2021, 51, 101242.	6.5	7
82	Cheap date. Nature, 1998, 396, 313-314.	27.8	6
83	Increased food intake with oxyntomodulin analogues. Peptides, 2015, 73, 95-100.	2.4	6
84	A glucagon analogue decreases body weight in mice via signalling in the liver. Scientific Reports, 2021, 11, 22577.	3.3	6
85	EFFECT OF OCTAPEPTIDE SOMATOSTATIN ANALOGUE (SMS 201â€995) ON PLASMA 7B2 (A NEUROENDOCRINE)	Ţj ETQq1	1 ₄ 0.78431
86	Pharmacotherapy for obesity: a field in crisis?. Expert Review of Endocrinology and Metabolism, 2011, 6, 563-577.	2.4	4
87	Pharmacokinetics and pharmacodynamics of subcutaneously administered PYY3–36 and its analogues in vivo. Lancet, The, 2015, 385, S28.	13.7	4
88	Learning curve of vessel cannulation in rats using cumulative sum analysis. Journal of Surgical Research, 2015, 193, 69-76.	1.6	3
89	Effects of Peptide YY on the Hypothalamic-Pituitary-Gonadal Axis in Healthy Men. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 833-838.	3.6	3
90	Acute Effects of Glucagon on Reproductive Hormone Secretion in Healthy Men. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 1899-1905.	3.6	3

#	Article	IF	CITATIONS
91	Biliopancreatic diversion in rats is associated with intestinal hypertrophy and with increased GLP-1, GLP-2 and PYY levels. Obesity Surgery, 2007, 17, 1193-1198.	2.1	2
92	Measuring the Pharmacokinetic Properties of Drugs with a Novel Surgical Rat Model. Journal of Investigative Surgery, 2017, 30, 162-169.	1.3	1
93	Reply: Clinical trial registry alone is not adequate: on the perception of possible endpoint switching and P-hacking. Human Reproduction, 2018, 33, 342-344.	0.9	1
94	SUN-LB044 Effects of Glucagon-Like Peptide-1 (GLP-1) on the Hypothalamic-Pituitary-Gonadal Axis in Healthy Men. Journal of the Endocrine Society, 2019, 3, .	0.2	1
95	Introductory chapter. , 2008, , 1-19.		0
96	Does Kisspeptin signaling offer a new way to treat infertility?. Expert Review of Obstetrics and Gynecology, 2009, 4, 477-481.	0.4	0
97	Obesity, gut hormones and knighthood. Expert Review of Endocrinology and Metabolism, 2013, 8, 225-227.	2.4	0
98	Patient Age Predicts the Delay before Survivors of Cancer Utilise Their Cryopreserved Sperm for Assisted Reproductive Technology. Blood, 2015, 126, 4481-4481.	1.4	0